Histone Deacetylase Inhibitors As Radiosensitisers: Effects on DNA Damage Signalling and Repair

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Jan 31

PMID 23361058

Citations 98

Authors

B Groselj

N L Sharma

F C Hamdy

M Kerr

A E Kiltie

Affiliations

Soon will be listed here.

Abstract

Many cancers display increased expression of histone deacetylases (HDACs) and therefore transcriptionally inactive chromatin, resulting in the downregulation of genes including tumour suppressor and DNA repair genes. Histone deacetylase inhibitors (HDACi) are a heterogeneous group of epigenetic therapeutics, showing promising anticancer effects in both pre-clinical and clinical settings, in particular the effect of radiosensitisation when administered in combination with radiotherapy. Radiotherapy remains one of the most common forms of cancer treatment, leading to cell death through the induction of DNA double-strand breaks (DSBs). Cells have developed mechanisms to repair such DSB through two major pathways: non-homologous end-joining and homologous recombination. Here, we explore the current evidence for the use of HDACi in combination with irradiation, focusing on the effects of HDACi on DNA damage signalling and repair in vitro. In addition, we summarise the clinical evidence for using HDACi with radiotherapy, a growing area of interest with great potential clinical utility.

Citing Articles

Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer.

Chan S, Yeo C, Hong B, Tan E, Beh C, Yeo E Exp Hematol Oncol. 2025; 14(1):5.

PMID: 39800760 PMC: 11727331. DOI: 10.1186/s40164-024-00590-8.

Multi-Target Inhibitor CUDC-101 Impairs DNA Damage Repair and Enhances Radiation Response in Triple-Negative Breast Cell Line.

Seane E, Nair S, Vandevoorde C, Bisio A, Joubert A Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598379 PMC: 11597529. DOI: 10.3390/ph17111467.

Histone deacetylase inhibitor, Trichostatin A mitigates ionizing radiation induced redox imbalance by regulating NRF2/GPX4/PINK1/PARKIN signaling in mice intestine.

Dahiya A, Sharma S, Agrawala P, Dutta A Mol Biol Rep. 2024; 51(1):943.

PMID: 39198316 DOI: 10.1007/s11033-024-09867-x.

HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks.

Cassandri M, Porrazzo A, Pomella S, Noce B, Zwergel C, Aiello F Cell Death Discov. 2024; 10(1):351.

PMID: 39107280 PMC: 11303816. DOI: 10.1038/s41420-024-02115-y.

Targeting histone deacetylase 6 (HDAC6) to enhance radiation therapy in meningiomas in a 2D and 3D in vitro study.

Na J, Shaji S, Hanemann C EBioMedicine. 2024; 105:105211.

PMID: 38917510 PMC: 11255518. DOI: 10.1016/j.ebiom.2024.105211.

References

Bratland A, Dueland S, Hollywood D, Flatmark K, Ree A . Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat Oncol. 2011; 6:33. PMC: 3086833. DOI: 10.1186/1748-717X-6-33. View

Shabason J, Tofilon P, Camphausen K . Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med. 2011; 15(12):2735-44. PMC: 3112261. DOI: 10.1111/j.1582-4934.2011.01296.x. View

Sharma N, Groselj B, Hamdy F, Kiltie A . The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. BJU Int. 2013; 111(4):537-42. DOI: 10.1111/j.1464-410X.2012.11647.x. View

Zhang F, Zhang T, Teng Z, Zhang R, Wang J, Mei Q . Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol Ther. 2009; 8(9):823-31. DOI: 10.4161/cbt.8.9.8143. View

Munshi A, Kurland J, Nishikawa T, Tanaka T, Hobbs M, Tucker S . Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res. 2005; 11(13):4912-22. DOI: 10.1158/1078-0432.CCR-04-2088. View

Candelaria M, Cetina L, Perez-Cardenas E, De la Cruz-Hernandez E, Gonzalez-Fierro A, Trejo-Becerril C . Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynaecol Oncol. 2010; 31(4):386-91. View

Wagner J, Hackanson B, Lubbert M, Jung M . Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics. 2011; 1(3-4):117-136. PMC: 3020651. DOI: 10.1007/s13148-010-0012-4. View

Rassool F, Tomkinson A . Targeting abnormal DNA double strand break repair in cancer. Cell Mol Life Sci. 2010; 67(21):3699-710. PMC: 3014093. DOI: 10.1007/s00018-010-0493-5. View

Nolan L, Johnson P, Ganesan A, Packham G, Crabb S . Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?. Br J Cancer. 2008; 99(5):689-94. PMC: 2528143. DOI: 10.1038/sj.bjc.6604557. View

10.

Lee J, Choy M, Ngo L, Foster S, Marks P . Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A. 2010; 107(33):14639-44. PMC: 2930422. DOI: 10.1073/pnas.1008522107. View

11.

Kuribayashi T, Ohara M, Sora S, Kubota N . Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation. Int J Mol Med. 2009; 25(1):25-9. View

12.

Kotian S, Liyanarachchi S, Zelent A, Parvin J . Histone deacetylases 9 and 10 are required for homologous recombination. J Biol Chem. 2011; 286(10):7722-7726. PMC: 3048658. DOI: 10.1074/jbc.C110.194233. View

13.

Masoudi A, Elopre M, Amini E, Nagel M, Ater J, Gopalakrishnan V . Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 2008; 28(4C):2437-42. View

14.

Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A . Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia. 2012; 26(7):1517-26. DOI: 10.1038/leu.2012.31. View

15.

Goodarzi A, Jeggo P, Lobrich M . The influence of heterochromatin on DNA double strand break repair: Getting the strong, silent type to relax. DNA Repair (Amst). 2010; 9(12):1273-82. DOI: 10.1016/j.dnarep.2010.09.013. View

16.

Ree A, Dueland S, Folkvord S, Hole K, Seierstad T, Johansen M . Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 2010; 11(5):459-64. DOI: 10.1016/S1470-2045(10)70058-9. View

17.

Miller K, Tjeertes J, Coates J, Legube G, Polo S, Britton S . Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol. 2010; 17(9):1144-51. PMC: 3018776. DOI: 10.1038/nsmb.1899. View

18.

Ropero S, Esteller M . The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2009; 1(1):19-25. PMC: 5543853. DOI: 10.1016/j.molonc.2007.01.001. View

19.

Khan O, Fotheringham S, Wood V, Stimson L, Zhang C, Pezzella F . HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A. 2010; 107(14):6532-7. PMC: 2851972. DOI: 10.1073/pnas.0913912107. View

20.

Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford J, Buggy J . HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A. 2007; 104(49):19482-7. PMC: 2148315. DOI: 10.1073/pnas.0707828104. View